Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments
- PMID: 9631086
- DOI: 10.1038/nbt1096-1239
Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments
Abstract
Disulfide-stabilized Fv fragments of antibodies (dsFv) are molecules in which the VH-VL heterodimer is stabilized by an interchain disulfide bond engineered between structurally conserved framework positions distant from complementarity-determining regions (CDRs). This method of stabilization is applicable for the stabilization of many antibody Fvs and has also been applied to a T-cell receptor Fv. A summary of the design strategy, and the construction and production of various dsFvs and dsFv-fusion proteins is presented. Included in the discussion are the biochemical features of dsFvs in comparison with scFvs, the effect of disulfide stabilization on Fv binding and activity, and various applications of dsFvs and dsFv-immunotoxins for tumor imaging and the treatment of solid tumors in animal models.
Similar articles
-
Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins.Clin Cancer Res. 1996 Feb;2(2):245-52. Clin Cancer Res. 1996. PMID: 9816166 Review.
-
Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv.Protein Eng. 1994 May;7(5):697-704. doi: 10.1093/protein/7.5.697. Protein Eng. 1994. PMID: 8073039
-
Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.Cancer Res. 1994 May 15;54(10):2714-8. Cancer Res. 1994. PMID: 8168102
-
Disulfide stabilization of antibody Fv: computer predictions and experimental evaluation.Protein Eng. 1995 Dec;8(12):1323-31. doi: 10.1093/protein/8.12.1323. Protein Eng. 1995. PMID: 8869646
-
Pharmacokinetics and biodistribution of genetically-engineered antibodies.Q J Nucl Med. 1998 Dec;42(4):225-41. Q J Nucl Med. 1998. PMID: 9973838 Review.
Cited by
-
Monoclonal antibody-based optical molecular imaging probes; considerations and caveats in chemistry, biology and pharmacology.Curr Opin Chem Biol. 2016 Aug;33:32-8. doi: 10.1016/j.cbpa.2016.05.015. Epub 2016 Jun 6. Curr Opin Chem Biol. 2016. PMID: 27281509 Free PMC article. Review.
-
Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability.Cancer Immunol Immunother. 2008 Dec;57(12):1879-90. doi: 10.1007/s00262-008-0518-1. Epub 2008 Apr 12. Cancer Immunol Immunother. 2008. PMID: 18408925 Free PMC article.
-
Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors.MAbs. 2021 Jan-Dec;13(1):1850395. doi: 10.1080/19420862.2020.1850395. MAbs. 2021. PMID: 33459147 Free PMC article.
-
Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy.Nat Commun. 2024 Jan 15;15(1):519. doi: 10.1038/s41467-024-44786-2. Nat Commun. 2024. PMID: 38225288 Free PMC article.
-
A modular IgG-scFv bispecific antibody topology.Protein Eng Des Sel. 2010 Apr;23(4):221-8. doi: 10.1093/protein/gzp077. Epub 2009 Dec 17. Protein Eng Des Sel. 2010. PMID: 20019028 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources